WHAT IS CLAIMED IS:

1. A method of treating atherosclerotic plaque rupture comprising administering to a mammal in need of such treatment, a safe and effective amount of a compound having a structure according to Formula (I):



(I)

wherein

A is alkyl, heteroalkyl, aryl or heteroaryl, substituted or unsubstituted ;

R_1 is $NHOR_2$, where R_2 is hydrogen or alkyl;

W is one or more of hydrogen, lower alkyl, or an alkylene bridge that forms a ring in addition to the ring depicted in Formula (I);

Y is independently one or more of hydroxy, SR_3, SOR_4, SO_2R_8, alkoxy, or amino, wherein the amino is of formula NR_6,R_7, wherein R_6 and R_7 are independently chosen from hydrogen, alkyl, heteroalkyl, heteroaryl, aryl, OR_3, SO_2R_8, COR_9, CSR_{10}, and $PO(R_{11})_2$;

R_3 is hydrogen, alkyl, aryl, or heteroaryl;

R_4 is alkyl, aryl, or heteroaryl;

each R_8 is independently chosen from group consisting of alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino;

R_9 is hydrogen, alkoxy, aryloxy, heteroaryloxy, alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino or alkylarylamino;

R_{10} is alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino, diarylamino or alkylarylamino;

R_{11} is alkyl, aryl, heteroaryl, or heteroalkyl;

Z is hydrogen, hydroxy, alkyl, or an alkylene or heteroalkylene bridge that forms a ring in addition to the ring depicted in Formula (I);

n is 1; and

provided that (i) when any one or more of R_3, R_4, R_8, R_9, R_{10}, R_{11}, W, Y or Z is itself, or together with another moiety forms, a heterocyclic moiety, that heterocyclic moiety is furan, and (ii) when W or Z is an alkylene or heteroalkylene bridge that forms a second ring fused to the ring depicted in Formula (I), that second ring does not include the ring carbon atom depicted in Formula (I) that is bonded to C(=O)-R_1; or

an optical isomer, diastereomer or enantiomer for Formula (I), or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof.

2. The method of Claim 1, wherein the compound is of structure:



(I)

wherein

A is aryl or heteroaryl, substituted or unsubstituted ;

R_1 is $NHOR_2$, where R_2 is hydrogen or alkyl;

W is one or more of hydrogen or lower alkyl;

Y is independently one or more of hydroxy, SR_3, SOR_4, SO_2R_8, alkoxy, or amino, wherein the amino is of formula NR_6,R_7, wherein R_6 and R_7 are independently chosen from hydrogen, alkyl, heteroalkyl, heteroaryl, aryl, OR_3, SO_2R_8, COR_9, CSR_{10} and $PO(R_{11})_2$;

R_3 is hydrogen, alkyl, aryl, or heteroaryl;

R_4 is alkyl, aryl, or heteroaryl;

each R_8 is independently chosen from the group consisting of alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino;

R_9 is hydrogen, alkoxy, aryloxy, heteroaryloxy, alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino or alkylarylamino;

R_{10} is alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino, diarylamino, or alkylarylamino;

R_{11} is alkyl, aryl, heteroaryl, or heteroalkyl;

Z is hydrogen; and

n is 1; or

an optical isomer, diastereomer or enantiomer for Formula (I), or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof.

3. The method of Claim 2, wherein the compound is selected from the group consisting of:
(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4R)-hydroxypyrrolidine;
(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-hydroxypyrrolidine;
(1*N*)-(4-Methoxyphenylsulfonyl)-(2S)-N-hydroxycarboxamido-(4R)-hydroxypyrrolidine;
(1*N*)-(4-Methoxyphenylsulfonyl)-(2S)-N-hydroxycarboxamido-(4S)-hydroxypyrrolidine;
(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-methoxypyrrolidine;
(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-(2-mercapto-benzothiazolyl)-pyrrolidine;
(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4R)-(2-mercaptobenzo-thiazolyl)-pyrrolidine;
(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-[(1*N*)-methyl-2-mercaptoimidazyl]-pyrrolidine;
(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4R)-[(1*N*)-methyl-2-mercaptoimidazyl]-pyrrolidine;
(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-phenoxypyrrolidine;
(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-(4-benzyloxy)-phenoxypyrrolidine;
(1*N*)-4-Methoxyphenylsulfonyl-(2R)-N-hydroxycarboxamido-(4S)-(3-N-phenylamino)-phenoxypyrrolidine;
(1*N*)-4-Methoxyphenylsulfonyl-(2R)-N-hydroxycarboxamido-(4S)-phenoxypyrrolidine;
(1*N*)-4-Methoxyphenylsulfonyl-(2R)-N-hydroxycarboxamido-(4S)-mercaptophenylpyrrolidine;
(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-(4-methoxyphenyl-thioloxy)-pyrrolidine;
(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-(3-methoxy-mercaptophenyl)-pyrrolidine;
(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-(n-hexylamino)-pyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-thiopyrrolidine;
(±)-(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(3S)-phenylpyrrolidine;
(1*N*)-(4-Methylphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-hydroxypyrrolidine;
(1*N*)-(3,4-Dimethoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4R)-hydroxypyrrolidine;
(1*N*)-(2-Nitro-4-methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4R)-hydroxypyrrolidine;
(1N)-4-nButoxyphenylsulfonyl-(2R)-N-hydroxycarboxamido-(4R)-hydroxypyrrolidine;
(1*N*)-(4-nButoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-hydroxypyrrolidine;
(1*N*)-(4-nButoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-(2-mercapto-benzothiazolyl)-pyrrolidine;
(1*N*)-(2-Nitro-4-methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-(2-mercapto-benzothiazolyl)-pyrrolidine;
(±)-(1*N*)-4-Methoxyphenylsulfonyl-(2R)-N-hydroxycarboxamido-5-pyrrolidinone;
(1*N*)-4-Methoxyphenylsulfonyl-(2R)-N-hydroxycarboxamido-(4,4R)-hydroxy-ethylpyrrolidine; and
(1*N*)-4-Methoxyphenylsulfonyl-(2R)-N-hydroxycarboxamido-(4S)-morpholinopyrrolidine.

4. The method according to Claim 3, wherein the compound is selected from the group consisting of:
(1*N*)-4-Phenoxyphenylsulfonyl-(2R)-N-hydroxycarboxamido- (4R)-hydroxypyrrolidine;
(1*N*)-4-n-Butoxyphenylsulfonyl-(2R)-N-hydroxycarboxamido-(4R)-hydroxypyrrolidine;
(1*N*)-4-n-Butoxyphenylsulfonyl-(2R)-N-hydroxycarboxamido-(4S)-hydroxypyrrolidine; and
(1*N*)-4-n-Butoxyphenylsulfonyl-(2R)-N-hydroxycarboxamido-(4S)-morpholinopyrrolidine.

5. A composition comprising: (a) a stent; (b) a drug releasing polymer; and (c) a safe and effective amount of a compound of Formula (I):



(I)

wherein

A is alkyl, heteroalkyl, aryl or heteroaryl, substituted or unsubstituted ;

R_1 is $NHOR_2$, where R_2 is hydrogen or alkyl;

W is one or more of hydrogen, lower alkyl, or an alkylene bridge that forms a ring in addition to the ring depicted in Formula (I);

Y is independently one or more of hydroxy, SR_3, SOR_4, SO_2R_8, alkoxy, or amino, wherein the amino is of formula NR_6,R_7, wherein R_6 and R_7 are independently chosen from hydrogen, alkyl, heteroalkyl, heteroaryl, aryl, OR_3, SO_2R_8, COR_9, CSR_{10}, and $PO(R_{11})_2$;

R_3 is hydrogen, alkyl, aryl, or heteroaryl;

R_4 is alkyl, aryl, or heteroaryl;

each R_8 is independently chosen from group consisting of alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino;

R_9 is hydrogen, alkoxy, aryloxy, heteroaryloxy, alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino or alkylarylamino;

R_{10} is alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino, diarylamino or alkylarylamino;

R_{11} is alkyl, aryl, heteroaryl, or heteroalkyl;

Z is hydrogen, hydroxy, alkyl, or an alkylene or heteroalkylene bridge that forms a ring in addition to the ring depicted in Formula (I);

n is 1; and

provided that (i) when any one or more of R_3, R_4, R_8, R_9, R_{10}, R_{11}, W, Y or Z is itself, or together with another moiety forms, a heterocyclic moiety, that heterocyclic moiety is furan, and (ii) when W or Z is an alkylene or heteroalkylene bridge that forms a second ring fused to the ring depicted in Formula (I), that second ring does not include the ring carbon atom depicted in Formula (I) that is bonded to $C(=O)-R_1$; or

an optical isomer, diastereomer or enantiomer for Formula (I), or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof.

6. The composition of Claim 5, wherein the compound is of structure:



(I)

wherein

A is aryl or heteroaryl, substituted or unsubstituted ;

R_1 is $NHOR_2$, where R_2 is hydrogen or alkyl;

W is one or more of hydrogen or lower alkyl;

Y is independently one or more of hydroxy, SR_3, SOR_4, SO_2R_8, alkoxy, or amino, wherein the amino is of formula NR_6,R_7, wherein R_6 and R_7 are independently chosen from hydrogen, alkyl, heteroalkyl, heteroaryl, aryl, OR_3, SO_2R_8, COR_9, CSR_{10} and $PO(R_{11})_2$;

R_3 is hydrogen, alkyl, aryl, or heteroaryl;

R_4 is alkyl, aryl, or heteroaryl;

each R_8 is independently chosen from the group consisting of alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino;

R_9 is hydrogen, alkoxy, aryloxy, heteroaryloxy, alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino or alkylarylamino;

R_{10} is alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino, diarylamino, or alkylarylamino;

R_{11} is alkyl, aryl, heteroaryl, or heteroalkyl;

Z is hydrogen; and

n is 1; or

an optical isomer, diastereomer or enantiomer for Formula (I), or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof.

7. The composition of Claim 6, wherein the compound is selected from the group consisting of:

(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4R)-hydroxypyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-hydroxypyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2S)-N-hydroxycarboxamido-(4R)-hydroxypyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2S)-N-hydroxycarboxamido-(4S)-hydroxypyrrolidine;
(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-methoxypyrrolidine;
(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-(2-mercapto-benzothiazolyl)-pyrrolidine;
(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4R)-(2-mercaptobenzo-thiazolyl)-pyrrolidine;
(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-[(1*N*)-methyl-2-mercaptoimidazyl]-pyrrolidine;
(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4R)-[(1*N*)-methyl-2-mercaptoimidazyl]-pyrrolidine;
(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-phenoxypyrrolidine;
(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-(4-benzyloxy)-phenoxypyrrolidine;
(1*N*)-4-Methoxyphenylsulfonyl-(2R)-N-hydroxycarboxamido-(4S)-(3-N-phenylamino)-phenoxypyrrolidine;
(1*N*)-4-Methoxyphenylsulfonyl-(2R)-N-hydroxycarboxamido-(4S)-phenoxypyrrolidine;
(1*N*)-4-Methoxyphenylsulfonyl-(2R)-N-hydroxycarboxamido-(4S)-mercaptophenylpyrrolidine;
(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-(4-methoxyphenyl-thioloxy)-pyrrolidine;
(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-(3-methoxy-mercaptophenyl)-pyrrolidine;
(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-(n-hexylamino)-pyrrolidine;
(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-thiopyrrolidine;
(±)-(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(3S)-phenylpyrrolidine;
(1*N*)-(4-Methylphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-hydroxypyrrolidine;
(1*N*)-(3,4-Dimethoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4R)-hydroxypyrrolidine;
(1*N*)-(2-Nitro-4-methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4R)-hydroxypyrrolidine;
(1N)-4-nButoxyphenylsulfonyl-(2R)-N-hydroxycarboxamido-(4R)-hydroxypyrrolidine;
(1*N*)-(4-nButoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-hydroxypyrrolidine;
(1*N*)-(4-nButoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-(2-mercapto-benzothiazolyl)-pyrrolidine;
(1*N*)-(2-Nitro-4-methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-(2-mercapto-benzothiazolyl)-pyrrolidine;
(±)-(1*N*)-4-Methoxyphenylsulfonyl-(2R)-N-hydroxycarboxamido-5-pyrrolidinone;

(1*N*)-4-Methoxyphenylsulfonyl-(2R)-N-hydroxycarboxamido-(4,4R)-hydroxy-ethylpyrrolidine; and

(1*N*)-4-Methoxyphenylsulfonyl-(2R)-N-hydroxycarboxamido-(4S)-morpholinopyrrolidine.

8. The composition of Claim 7, wherein the compound is selected from the group consisting of:
(1*N*)-Phenoxyphenylsulfonyl)-(2R)-carbomethoxy-(4R)-hydroxypyrrolidine;
(1*N*)-4-^{n}Butoxyphenylsulfonamido-(2R)-*N*-hydroxycarboxamido-(4R)-hydroxypyrrolidine; and
(1*N*)-4-^{n}Butoxyphenylsulfonyl)-2R)-*N*-hydroxycarboxamido-(4S)-hydroxypyrrolidine.

9 A method of treating restenosis comprising administering to a mammal in need of such treatment, a safe and effective amount of a compound of having a structure according to Formula (I):



(I)

wherein

A is alkyl, heteroalkyl, aryl or heteroaryl, substituted or unsubstituted ;

R_1 is $NHOR_2$, where R_2 is hydrogen or alkyl;

W is one or more of hydrogen, lower alkyl, or an alkylene bridge that forms a ring in addition to the ring depicted in Formula (I);

Y is independently one or more of hydroxy, SR_3, SOR_4, SO_2R_8, alkoxy, or amino, wherein the amino is of formula NR_6,R_7, wherein R_6 and R_7 are independently chosen from hydrogen, alkyl, heteroalkyl, heteroaryl, aryl, OR_3, SO_2R_8, COR_9, CSR_{10}, and $PO(R_{11})_2$;

R_3 is hydrogen, alkyl, aryl, or heteroaryl;

R_4 is alkyl, aryl, or heteroaryl;

each R_8 is independently chosen from group consisting of alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino;

R_9 is hydrogen, alkoxy, aryloxy, heteroaryloxy, alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino or alkylarylamino;

R_{10} is alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino, diarylamino or alkylarylamino;

R_{11} is alkyl, aryl, heteroaryl, or heteroalkyl;

Z is hydrogen, hydroxy, alkyl, or an alkylene or heteroalkylene bridge that forms a ring in addition to the ring depicted in Formula (I);

n is 1; and

provided that (i) when any one or more of R_3, R_4, R_8, R_9, R_{10}, R_{11}, W, Y or Z is itself, or together with another moiety forms, a heterocyclic moiety, that heterocyclic moiety is furan, and (ii) when W or Z is an alkylene or heteroalkylene bridge that forms a second ring fused to the ring depicted in Formula (I), that second ring does not include the ring carbon atom depicted in Formula (I) that is bonded to C(=O)-R_1; or

an optical isomer, diastereomer or enantiomer for Formula (I), or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof.

10. The method of Claim 9, wherein the compound is of structure:



(I)

wherein

A is aryl or heteroaryl, substituted or unsubstituted ;

R_1 is $NHOR_2$, where R_2 is hydrogen or alkyl;

W is one or more of hydrogen or lower alkyl;

Y is independently one or more of hydroxy, SR_3, SOR_4, SO_2R_8, alkoxy, or amino, wherein the amino is of formula NR_6,R_7, wherein R_6 and R_7 are independently chosen from hydrogen, alkyl, heteroalkyl, heteroaryl, aryl, OR_3, SO_2R_8, COR_9, CSR_{10} and $PO(R_{11})_2$;

R_3 is hydrogen, alkyl, aryl, or heteroaryl;

R_4 is alkyl, aryl, or heteroaryl;

each R_8 is independently chosen from the group consisting of alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino;

R_9 is hydrogen, alkoxy, aryloxy, heteroaryloxy, alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino or alkylarylamino;

R_{10} is alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino, diarylamino, or alkylarylamino;

R_{11} is alkyl, aryl, heteroaryl, or heteroalkyl;

Z is hydrogen; and

n is 1; or

an optical isomer, diastereomer or enantiomer for Formula (I), or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof.

11) The method of Claim 10, wherein the compound is selected from the group consisting of:

(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4R)-hydroxypyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-hydroxypyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2S)-N-hydroxycarboxamido-(4R)-hydroxypyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2S)-N-hydroxycarboxamido-(4S)-hydroxypyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-methoxypyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-(2-mercapto-benzothiazolyl)-pyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4R)-(2-mercaptobenzo-thiazolyl)-pyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-[(1*N*)-methyl-2-mercaptoimidazyl]-pyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4R)-[(1*N*)-methyl-2-mercaptoimidazyl]-pyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-phenoxypyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-(4-benzyloxy)-phenoxypyrrolidine;

(1*N*)-4-Methoxyphenylsulfonyl-(2R)-N-hydroxycarboxamido-(4S)-(3-N-phenylamino)-phenoxypyrrolidine;

(1*N*)-4-Methoxyphenylsulfonyl-(2R)-N-hydroxycarboxamido-(4S)-phenoxypyrrolidine;

(1*N*)-4-Methoxyphenylsulfonyl-(2R)-N-hydroxycarboxamido-(4S)-mercaptophenylpyrrolidine;
(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-(4-methoxyphenyl-thioloxy)-pyrrolidine;
(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-(3-methoxy-mercaptophenyl)-pyrrolidine;
(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-(n-hexylamino)-pyrrolidine;
(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-thiopyrrolidine;
(±)-(1*N*)-(4-Methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(3S)-phenylpyrrolidine;
(1*N*)-(4-Methylphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-hydroxypyrrolidine;
(1*N*)-(3,4-Dimethoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4R)-hydroxypyrrolidine;
(1*N*)-(2-Nitro-4-methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4R)-hydroxypyrrolidine;
(1N)-4-nButoxyphenylsulfonyl-(2R)-N-hydroxycarboxamido-(4R)-hydroxypyrrolidine;
(1*N*)-(4-nButoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-hydroxypyrrolidine;
(1*N*)-(4-nButoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-(2-mercapto-benzothiazolyl)-pyrrolidine;
(1*N*)-(2-Nitro-4-methoxyphenylsulfonyl)-(2R)-N-hydroxycarboxamido-(4S)-(2-mercapto-benzothiazolyl)-pyrrolidine;
(±)-(1*N*)-4-Methoxyphenylsulfonyl-(2R)-N-hydroxycarboxamido-5-pyrrolidinone;
(1*N*)-4-Methoxyphenylsulfonyl-(2R)-N-hydroxycarboxamido-(4,4R)-hydroxy-ethylpyrrolidine; and
(1*N*)-4-Methoxyphenylsulfonyl-(2R)-N-hydroxycarboxamido-(4S)-morpholinopyrrolidine.

12. The method Claim 11, wherein the compound is selected from the group consisting of:
(1*N*)-4-Phenoxyphenylsulfonyl-(2R)-N-hydroxycarboxamido- (4R)-hydroxypyrrolidine;
(1*N*)-4-n-Butoxyphenylsulfonyl-(2R)-N-hydroxycarboxamido-(4R)-hydroxypyrrolidine;
(1*N*)-4-n-Butoxyphenylsulfonyl-(2R)-N-hydroxycarboxamido-(4S)-hydroxypyrrolidine; and
(1*N*)-4-n-Butoxyphenylsulfonyl-(2R)-N-hydroxycarboxamido-(4S)-morpholinopyrrolidine.